Human antibodies targeting CD30+ lymphomas

Human Antibodies

Volumn 21, Issue 1-2, 2012, Pages 13-28

  Wezler, Xenia ^a   Hust, Michael ^a   Helmsing, Saskia ^a   Schirrmann, Thomas ^a   Dübel, Stefan ^a  

^a TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

Author keywords

ALCL; antibody phage display; CD30; Hodgkin lymphoma; Immunotherapy; lymphoma; scFv; scFv Fc

Indexed keywords

CD30 ANTIGEN; FC RECEPTOR; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SH133 B5; MONOCLONAL ANTIBODY SH133 F9; MONOCLONAL ANTIBODY SH133 G9; MONOCLONAL ANTIBODY SH133 H4; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG STABILITY; ENDOCYTOSIS; ESCHERICHIA COLI; FLOW CYTOMETRY; GENE LIBRARY; HODGKIN DISEASE; HUMAN; HUMAN CELL; IC 50; INTERNALIZATION; LARGE CELL LYMPHOMA; LYMPHOMA CELL; PH; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; T CELL LYMPHOMA;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, CD30; CELL LINE, TUMOR; GENE LIBRARY; HEK293 CELLS; HUMANS; IMMUNOTHERAPY; LYMPHOMA; PEPTIDE LIBRARY; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES;

EID: 84865485853     PISSN: 10932607     EISSN: 1875869X     Source Type: Journal    
DOI: 10.3233/HAB-2012-0258     Document Type: Article

References (42)

1. R. K̈uppers, J. Yahalom and A. Josting, Advances in biology, diagnostics, and treatment of Hodgkin's disease, Biol Blood Marrow Transplant 12(1 Suppl 1) (2006), 66-76.
2. L. Specht et al., Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: Ameta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group, J Clin Oncol 16(3) (1998), 830-843.
3. P. Hoskin, P. Smith and D. Linch, Late morbidity and survival in early stage Hodgkin's disease treated with involved field or wide field radiotherapy alone, Annals Of Oncology (2002), 13-65.
4. H.P. Gerber, Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma, Biochem Pharmacol 79(11) (2010), 1544-1552.
5. S. Nakamura et al., Anaplastic large cell lymphoma: A distinct molecular pathologic entity: A reappraisal with special reference to p80(NPM/ALK) expression, Am J Surg Pathol 21(12) (1997), 1420-1432.
6. S. Park et al., Primary systemic anaplastic large cell lymphoma in a singleKorean institution: Clinical characteristics and treatment outcome, J Korean Med Sci 21(4) (2006), 633-638.
7. S. Braschoss et al., New anti-CD30 human pancreatic ribonuclease- based immunotoxin reveals strong and specific cytotoxicity in vivo, Leuk Lymphoma 48(6) (2007), 1179-1186.
8. M. Watanabe et al., Hypomethylation of CD30 CpG islands with aberrant JunB expression drives CD30 induction in Hodgkin lymphoma and anaplastic large cell lymphoma, Laboratory Investigation 88 (2008), 48-57.
9. R. Horie and T. Watanabe, CD30: Expression and function in health and disease, Semin Immunol 10(6) (1998), 457-470.
10. B. Falini et al., CD30 (Ki-1)molecule: A newcytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy, Blood 85(1) (1995), 1-14.
11. H. Stein et al., CD30(+) anaplastic large cell lymphoma: A review of its histopathologic, genetic, and clinical features, Blood 96(12) (2000), 3681-3695.
12. A. Wahl et al., The anti-CD30 monoclonal antibody SGN- 30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease, Cancer Res 62(13) (2002), 3736-3742.
13. K. Kawakami et al., Targeted anticancer immunotoxins and cytotoxic agents with direct killing moieties, Scientific World Journal 6 (2006), 781-790.
14. L.C. Pinter-Brown, SGN-30: A basis for the effective treatment of CD30 positive hematopoietic malignancies, Expert Opin Investig Drugs 17(12) (2008), 1883-1887.
15. G. Ḧubinger et al., CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299, Oncogene 20(5) (2001), 590-598.
16. B.B̈oll, P. Borchmann and A. Engert, ExperimentelleTherapie des Hodgkin-Lymphoms, Onkologe 16 (2010), 48-54.
17. C. Menzel et al., Human antibody RNase fusion protein targeting CD30+ lymphomas, Blood 111(7) (2008), 3830-3837.
18. B. Falini et al., In vivo targeting of Hodgkin and Reed- Sternberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30): Immunohistological evidence, Br J Haematol 82(1) (1992), 38-45.
19. M. Hust et al., A human scFv antibody generation pipeline for proteome research, J Biotechnol 152 (2011), 159-170.
20. M.I. Kirsch et al., Development of human antibody fragments using antibody phage display for the detection and diagnosis of Venezuelan equine encephalitis virus (VEEV), BMCBiotechnology 8(66) (2008).
21. S.C. Pohl et al., A cassette vector system for the rapid cloning and production of bispecific tetravalent antibodies, Antibodies 1(1) (2012), 19-38.
22. T. Schirrmann and K. B̈ussow, Transient production of scFv-Fc fusion proteins in mammalian cells, in: Antibody Engineering, (Vol 2, ed.), R. Kontermann and S. D̈ubel, Springer-Verlag, 2010, pp. 387-400.
23. T. Schirrmann and M. Hust, Construction of human antibody gene libraries and selection of antibodies by phage display, Methods Mol Biol 651 (2010), 177-209.
24. J. Sambrook and D. Russell, Molecular cloning: A laboratory manual. New York: Cold Spring Harbor Laboratory Press, 2001, 3nd ed.
25. M. Hust et al., Improved microtitre plate production of single chain Fv fragments in Escherichia coli, N Biotechnol 25 (2009), 424-428.
26. S. Mollova et al., Analysis of single chain antibody sequences using the VBASE2 Fab analysis tool, Antibody Engineering, (2nd ed.), Heidelberg/New York: Springer Verlag, 2010, pp. 3-10.
27. M. Hust et al., Single chain Fab (scFab) fragment, BMC Biotechnol 7(14) (2007).
28. M. Palanca-Wessels and O. Press, Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas, Cancer Immunol Immunother 116(4 Suppl) (2010), 1126-1133.
29. A. Jona and A. Younes, Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma, Blood Rev 24(6) (2010), 233-238.
30. K.V. Foyil and N.L. Bartlett, Anti-CD30 Antibodies for Hodgkin lymphoma, Curr Hematol Malig Rep 5(3) (2010), 140-147.
31. H. Schellekens, Factors influencing the immunogenicity of therapeutic proteins, Nephrol Dial Transplant 20(Suppl 6) (2005), 3-9.
32. R.M. Sharkey and D.M. Goldenberg, Targeted therapy of cancer: New prospects for antibodies and immunoconjugates, CA Cancer J Clin 56(4) (2006), 226-243.
33. M. Mathew and R.S. Verma, Humanized immunotoxins: A new generation of immunotoxins for targeted cancer therapy, Cancer Sci 100(8) (2009), 1359-1365.
34. M. Jain, N. Kamal and S. Batra, Engineering antibodies for clinical applications, Trends Biotechnol 25(7) (2007), 307- 316.
35. G. Adams et al., Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies, Cancer Res 58(3) (1998), 485-490.
36. G. Adams et al., High affinity restricts the localization and tumor penetration of single-chain fv antibodymolecules, Cancer Res 61(12) (2001), 4750-4755.
37. N. Okeley et al., Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate, Clin Cancer Res 16(3) (2010), 888-897.
38. J. Lee et al., Receptor mediated uptake of peptides that bind the human transferrin receptor, Eur J Biochem 268(7) (2001), 2004-2012.
39. H. Hansen et al., CD30 shedding from Karpas 299 lymphoma cells ismediated byTNF-alpha-converting enzyme, J Immunol 165(12) (2000), 6703-6709.
40. H. Durkop et al., Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease, Cell 68(3) (1992), 421-427.
41. S.Y. Lee, C.G. Park and Y. Choi, T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptorassociated factors, J ExpMed 183(2) (1996), 669-674.
42. S. Ansieau et al., Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30- induced nuclear factor kappa B activation, Proc Natl Acad Sci U S A 93(24) (1996), 14053-14058.